Molplex is now hiring at Biohub, Alderley Park.
Molplex is a discovery-driven pharmaceutical business building a commercially attractive pipeline of new drugs in oncology, infection and other therapeutic areas. Founded in 2010 with technology that drives down the rate of failure, we have now won significant new funding to support the expansion of our discovery pipeline. Our ambition for the next 10 years is to create a new major global pharmaceutical business, with growth powered by the invention of high quality pre-clinical candidates for licensing. The new funding will enables us to take a major step towards that ambition and we are looking for equally ambitious people to help us succeed.
We have 17 new positions available at the Biohub facility in Alderley Park, Macclesfield from December 2013. For further information please visit Molplex careers.
Molplex wins UK Government RGF funding to establish an Optiplex laboratory to deliver new drugs for currently untreatable infections
"Department for Business, Innovation and Skills
Selected projects and programmes for the fourth round of the government’s Regional Growth Fund (RGF) will be announced today (Thursday 11 July) by the Deputy Prime Minister, Nick Clegg.
The Deputy Prime Minister announced that 102 companies and projects that applied for funding have been successful, following the most competitive round of the Fund so far.
The companies will take a share of a £506 million pot of funding to attract significant private sector investment and create thousands of jobs across the country."
For more :
Molplex raises £350,000 from the North West Fund for Biomedical
Molplex today announced it has raised £350,000 from the UK’s North West Fund for Biomedical, a fund managed by Spark Impact and funded jointly by the ERDF and the European Investment Bank.
The funds will allow Molplex to extend its automated drug discovery technology platform and advance its current pipeline of internal and partnered discovery projects, including the development of new medicines for Dengue Virus, new antibiotics for resistant bacteria, persistent Tuberculosis, and other programmes for serious human diseases. The company drug discovery programmes focus on infectious diseases, dermatology and cancer.
Molplex will set up a base in the North West of England to host its High-Performance Computing requirements, in addition to its administrative and managerial roles. Laboratory operations will remain in the North East.
Molplex CEO David Leahy commented “We would like to thank The North West Fund for Biomedical for supporting our transformation into the first of a new class of an ultra-effective drug discovery business. Molplex’s novel approach to the automation of drug discovery decision making can radically lower the cost of inventing new medicines, while increasing the quality of the new drug candidates. This funding creates an opportunity for us to convert that promise into reality.”
Penny Attridge,senior investment director at SPARK Impact and fund manager for The North West Fund for Biomedical, said: “We are really excited to be working with David and the team from Molplex and see a bright future for the company.”
Law firm Ward Hadaway advised the Fund in the investment, while Turner Parkinson advised the company. Epiphany Capital advised the company in the fund raising.